Top 5 articles in ankylosing spondylitis from 2020
Click Here to Manage Email Alerts
Healio Rheumatology compiled a list of the news in ankylosing spondylitis, including expert insight on pain management, drug updates and tips on diagnosis.
European Commission approves upadacitinib for PsA, ankylosing spondylitis
The European Commission has extended approval for AbbVie’s upadacitinib 15 mg to treat adult patients with active psoriatic arthritis and adult patients with active ankylosing spondylitis, according to a company press release. Read more.
Secukinumab provides 'significant, sustained' fatigue reduction in ankylosing spondylitis
Secukinumab demonstrated rapid, stained improvements in fatigue for up to 3 years among patients with ankylosing spondylitis, according to data published in Arthritis Care & Research. Read more.
Ankylosing spondylitis diagnosis, treatment based on a ‘constellation of symptoms’
Accurately diagnosing ankylosing spondylitis is a challenge for physicians, who must rely on a combination of symptoms and inflammation in place of a definitive blood marker. In this interview, an expert discusses what to look for in diagnosis and treatment initiation and where research is headed to make this a pathway for practitioners and patients. Read more.
Tofacitinib brings rapid clinical response in ankylosing spondylitis
Patients with ankylosing spondylitis demonstrated rapid clinical response to tofacitinib, which produced significantly greater efficacy than placebo, but with more adverse events, according to a speaker at ACR Convergence 2020. Read more.
Pain, fatigue persistent in ankylosing spondylitis despite TNF inhibitor use
Pain and fatigue levels remain high among patients with ankylosing spondylitis despite apparent disease control with biologic therapies, such as TNF inhibitors, according to a global survey published in the Journal of Clinical Rheumatology. Read more.